NIMHD Forecast RFA-MD-27-004: $3 Million and 10 R34 Planning Grants for Native Hawaiian and Pacific Islander Health, Applications Due February 16, 2027

Academic PIs and NIH-funded investigators in Native Hawaiian and Pacific Islander health have a named target: NIMHD forecast RFA-MD-27-004 on August 25, 2026 — a $3 million R34 set-aside with applications due February 16, 2027 — on its Grants.gov listing.

That single line contains more actionable specificity than most investigators in this space have had in a decade. Native Hawaiian and Pacific Islander health research has been chronically starved not because the disparities are small — NIMHD's own framing acknowledges that NHPI communities "disproportionately experience negative health outcomes and limited health care access" — but because the population has spent thirty years aggregated into an "Asian American and Pacific Islander" bucket that statistically erases it. RFA-MD-27-004 is the first NIMHD funding announcement to put "Native Hawaiian and Pacific Islander" in the title, alone, with money attached.

What NIMHD Forecast on August 25, and What It Is Not

The Grants.gov record for opportunity 363713 is a forecast, not a live solicitation. That distinction governs everything you do in the next ninety days. NIMHD published it on August 25, 2026 under CFDA 93.307 (Minority Health and Health Disparities Research) and 93.310 (Trans-NIH Research Support), stating its intent to publish a Notice of Funding Opportunity for planning grants supporting "preparatory, feasibility, and pilot activities that advance intervention development or solutions-oriented etiologic studies aimed at improving health and reducing health disparities outcomes among Native Hawaiian and Pacific Islander (NHPI) populations."

The dates NIMHD committed to:

• Estimated NOFO posting: December 16, 2026
• Estimated application due date: February 16, 2027
• Estimated award and project start: September 30, 2027
• Fiscal year: 2027

The money: $3,000,000 in estimated total program funding across approximately 10 awards, with no cost sharing required. Scientific contact runs through the NIMHD Division of Integrative Biological and Behavioral Sciences at NIMHDDIBBSScientificTeam@mail.nih.gov.

A forecast is a commitment of intent, not a legal obligation. NIMHD can change the funding level, shift the dates, or let the announcement lapse. But a forecast with a specific dollar figure, a specific award count, a specific activity code, and a named division contact is a substantially harder commitment than the vague "we anticipate future opportunities" language institutes use when they are hedging. Treat it as real, and treat the sixteen weeks between now and December 16 as your actual preparation window.

Ten Awards, $3 Million, and the Arithmetic That Should Shape Your Aim

Divide $3,000,000 by 10 awards and you get $300,000 per project. That is the number to plan against, and it tells you what kind of science NIMHD is buying.

NIH R34 planning grants typically cap at $450,000 in direct costs across a three-year project period, with a per-year ceiling around $225,000 — though caps vary by institute and by announcement, and NIMHD has not yet published the specific limits for this one. If the eventual NOFO holds to a three-year period, a $300,000 average total-cost award implies budgets meaningfully below the R34 ceiling. If it runs two years, the per-year figure is more comfortable. Either way, this is not a mechanism for running a definitive trial. It is a mechanism for earning the right to propose one.

The "Clinical Trial Optional" designation matters here. You may include a pilot or feasibility trial, or you may not — and NIMHD's own description leans toward the preparatory end: formative studies, planning, adapting, pilot-testing, feasibility and acceptability testing. Investigators who submit a fully-powered efficacy trial dressed as a planning grant will be told they mismatched the mechanism. Investigators who submit a genuine feasibility package with a credible path to a subsequent R01 are writing to the announcement.

Ten awards is also a meaningfully large slate for a population-specific RFA. Compare it to NIMHD's companion forecast, RFA-MD-27-001, an American Indian and Alaska Native cancer outcomes initiative posted July 16, 2026 with the same $3 million but structured as a limited competition with a single award and a January 25, 2027 deadline. Same institute, same fiscal year, same total dollars, radically different competitive geometry. RFA-MD-27-004 is open, distributed, and built for early-stage teams. If you have been waiting for an entry point, this is a more favorable one than the headline dollar figure suggests.

Why "Pacific Islander" in the Title Is the Substantive News

NIH has funded Native American health research for years. The active R34 in that portfolio, PAR-25-378 (Intervention Research to Improve Native American Health, deadline January 7, 2027), supports etiologic work, intervention development, and dissemination research in Native American populations — but its scope is organized around American Indian, Alaska Native, and Native Hawaiian communities, with Pacific Islander populations sitting awkwardly outside or at the margins of the definition. Samoan, Chamorro, Tongan, Fijian, Marshallese, and Micronesian communities have had no dedicated NIH mechanism naming them.

Two things changed. NIMHD established its NHPI Health Research Office in 2024, with a mandate covering disease disparities, career development for NHPI investigators, and research-capacity partnerships with academic institutions and NHPI-serving organizations. And in March 2024, OMB's revision to Statistical Policy Directive No. 15 required federal data collection to report Native Hawaiian, Samoan, Chamorro, Tongan, Fijian, and Marshallese populations as distinct categories rather than folding them into a broader aggregate.

RFA-MD-27-004 is what those two structural changes look like when they reach a funding line. The office now exists; the data infrastructure to detect disparities at the disaggregated level now exists; the announcement follows. That sequencing is worth understanding because it tells you what reviewers will reward — proposals that actually use disaggregated data and name specific communities, rather than proposals that treat "NHPI" as an undifferentiated block. A study designed around Marshallese diabetes outcomes in Arkansas and a study designed around Native Hawaiian maternal morbidity in Hawai'i are different sciences, and the announcement's framing invites you to say which one you are doing.

"Co-developed with Community Partners" Is a Requirement, Not a Garnish

The forecast contains one sentence that should reorganize your timeline: "Projects must be co-developed with community partners."

Not "should include community engagement." Not "partnerships are encouraged." Must be co-developed. In practice, review panels for community-engaged NIMHD announcements read letters of support closely and can distinguish a partnership assembled in the four weeks before submission from one that predates the announcement. If you do not currently have a working relationship with a Native Hawaiian health system, a Pacific Islander community organization, a Marshallese or Chamorro community health worker network, or a comparable partner, your critical path is not the specific aims page. It is the relationship — and sixteen weeks is a compressed but workable runway to build one honestly.

Eligibility is unusually broad, which supports this. The forecast's applicant list spans public and private institutions of higher education, nonprofits with and without 501(c)(3) status, Native American tribal governments and tribal organizations, state, county, city, and special-district governments, U.S. territories and possessions, faith-based and community-based organizations, regional organizations, small businesses and other for-profits, and non-domestic entities. The inclusion of territories and foreign institutions is not incidental for a population distributed across Hawai'i, Guam, American Samoa, the Northern Mariana Islands, and the Freely Associated States. Community organizations can hold the award directly, or serve as a genuine co-applicant rather than a subcontracted afterthought.

The Three Areas of Interest Read Like a Menu — Pick One

NIMHD named three areas of interest, and they are narrow enough to be useful:

1. Formative studies identifying novel or understudied contributors to poor health outcomes and chronic diseases such as cancer and diabetes.
2. Planning, adapting, and pilot-testing interventions for prevention, early detection, or control of maternal morbidity, infant health problems, or high-prevalence diseases.
3. Feasibility and acceptability testing of strategies to reduce behavioral risk factors — physical inactivity, poor nutrition, smoking — and promote sustained behavior change with measurable health outcomes.

"Include, but are not limited to" gives you room, but with roughly 10 awards available, the safest position is squarely inside one of the three. Note the third bullet's insistence on "measurable health outcomes." Behavior-change feasibility studies that end at self-reported intention are being pre-emptively discouraged.

This is the same discipline that separates funded from unfunded applications across NIH's set-aside RFAs generally — the pattern we traced through NCI's 2027 community oncology cycle in our analysis of the NCORP renewal RFAs and their $147.5 million across three announcements. Set-aside money rewards applicants who write to the announcement's stated priorities with near-literal fidelity, not those who reframe an existing project to fit.

What to Do Before December 16

Four concrete moves, in order of how long they take.

Start the partnership now. If you need a community co-developer, sixteen weeks is enough time to build a real one and not enough time to fake one. Reach out this month.

Email the program officers. The NIMHD Division of Integrative Biological and Behavioral Sciences scientific team is reachable at NIMHDDIBBSScientificTeam@mail.nih.gov. Ask whether the December 16 posting date is holding, whether budget caps will follow the standard R34 structure, and whether your concept fits the announcement's scope. Program officers answer these questions, and a pre-submission conversation is the cheapest risk reduction available to you.

Plan for a February 16, 2027 submission, then check the actual NOFO. Forecast dates move. When RFA-MD-27-004 posts in the NIH Guide, the real due date, budget cap, project period, and any letter-of-intent requirement will be in it. Do not build a schedule that has no slack.

Line up your disaggregated data now. Whatever community you are proposing to work with, the evidence base you cite should reflect the post-SPD-15 reporting environment. Proposals leaning on decade-old aggregated AAPI statistics will look dated to a review panel convened specifically because that aggregation failed.

Find adjacent live opportunities while you wait. RFA-MD-27-004 does not accept applications for another four months, but PAR-25-378 closes January 7, 2027, and NIMHD's broader portfolio has several open announcements with earlier deadlines. Search active NIH minority health and health disparities opportunities on Granted to see what is open right now, filter by mechanism and deadline, and identify a bridge award while the NHPI R34 works through its posting cycle.

Ten awards, $3 million, and a population that has waited a long time for an announcement with its own name on it. The window opens December 16.